NCT00402779View on ClinicalTrials.gov

Erlotinib Prevention of Oral Cancer (EPOC)

PHASE3CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

November 3, 2006

Primary Completion Date

June 4, 2018

Study Completion Date

June 4, 2018

Conditions
Oral Cancer
Interventions
DRUG

Erlotinib

150 mg by mouth daily

DRUG

Placebo

Tablet by mouth daily

Trial Locations (4)

10021

Memorial Sloan Kettering Cancer Center, New York

30322

Emory University Winship Cancer Institute, Atlanta

60637

The University of Chicago, Chicago

77030

The Univeristy of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00402779 - Erlotinib Prevention of Oral Cancer (EPOC) | Biotech Hunter | Biotech Hunter